Bone marrow mesenchymal stem cells-derived exosomes protect against β-cell destruction models and kidney injury by suppressing ferroptosis

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

• Level A · Stronger Clinical Evidence
• Level B · Emerging clinical evidence with positive signals
• Level C · Early human research exploring benefits
• Level D · Scientific groundwork from lab and animal studies
• Emerging · Emerging topic under active research

Abstract (original English)

Bone marrow mesenchymal stem cell-derived exosomes (BMSC-EXOs) exhibit therapeutic potential in type 1 diabetes mellitus (T1D). In a streptozotocin (STZ)-induced T1D mouse model, BMSC-EXOs reduced hyperglycemia, prevented weight loss, and alleviated early-stage diabetic kidney injury. These protective effects were associated with preserving pancreatic islet structure, restoring β-cell insulin production, and reducing oxidative stress. Mechanistically, BMSC-EXOs inhibited ferroptosis by up-regulating Glutathione peroxidase 4 (GPX4) expression, decreasing lipid peroxidation, and preventing β-cell and kidney damage. These findings indicate that BMSC-EXOs protect against STZ-induced β-cell destruction models and T1D-related complications by inhibiting ferroptosis, presenting a potential therapeutic approach for diabetes management.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.